




Selectivity matters

Filgotinib is a highly selective JAK1 inhibitor




1: A Pardanani, et al, *Leukemia* (2013) 27, 1322–1327



Hemoglobin

EPO-JAK2 selectivity

Hb mean CFB (g/dL), W12



Monitoring required


*Note: data from separate RA studies not conducted by the Company.
filgotinib – Westhovens et al, and Kavanaugh et al, ARD 2016; baricitinib – Dougados et al, Annrheumdis 2016, RA-BUILD;
tofacitinib – FDA AdComm briefing document May 2012; upadacitinib – Genovese et al A&R 2016 BALANCE 2.*



NK cells

IL15 - JAK3 selectivity

NK cells mean CFB (%), W12



Monitoring total lymphocytes required

Note: data from separate RA studies not conducted by the Company.

filgotinib – Westhovens et al, and Kavanaugh et al, ARD 2016; baricitinib – *Dougados et al, Annrheumdis 2016, RA-BUILD and Tanaka EULAR 2016 abstract RA-BEAM; tofacitinib – Van Vollenhoven abstract 2013, ** median CFB at W6;


upadacitinib – Genovese et al A&R 2016 BALANCE 2.



Herpes zoster

IFN-driven

Herpes zoster cases (%)




Note: data from separate RA studies not conducted by the Company.
filgotinib – Westhovens et al, and Kavanaugh et al, ARD 2016; baricitinib – Winthrop et al EULAR abstract 2016;
tofacitinib – Winthrop et al ArthRheum 2014; upadacitinib – Genovese et al A&R 2016 BALANCE 2.



Lipid improvement

JAK1-selectivity

LDL/HDL mean CFB, W12, inversed



Note: data from separate RA studies not conducted by the Company.

filgotinib – Westhovens et al, and Kavanaugh et al, ARD 2016; baricitinib – Smolen et al EULAR abstract 2016; tofacitinib – Charles-Schoeman et al ArthRheum 2016; upadacitinib – Genovese et al A&R 2016 BALANCE 2, Kremer et al A&R 2016 BALANCE 1.